Published in Cell on September 10, 2015
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell (2016) 2.65
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (2016) 1.95
Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Oncogene (2016) 1.39
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res (2015) 1.09
Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med (2016) 0.90
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov (2016) 0.86
Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells. Oncotarget (2016) 0.85
ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors. EMBO Mol Med (2016) 0.83
Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Ther (2016) 0.83
Regulatory circuits of T cell function in cancer. Nat Rev Immunol (2016) 0.81
Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients. J Transl Med (2016) 0.78
Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? Semin Immunol (2016) 0.78
Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. Oncotarget (2016) 0.77
Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol (2016) 0.77
BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts. Cell Rep (2016) 0.77
Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol (2017) 0.77
MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor. Oncotarget (2017) 0.76
Mapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seq. Oncotarget (2016) 0.76
Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. Br J Cancer (2016) 0.76
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med (2016) 0.76
The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol (2017) 0.75
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med (2017) 0.75
Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response. Stem Cell Reports (2017) 0.75
A stochastic model for immunotherapy of cancer. Sci Rep (2016) 0.75
MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. Pigment Cell Melanoma Res (2017) 0.75
Precision medicine driven by cancer systems biology. Cancer Metastasis Rev (2017) 0.75
Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors. Cancer Res (2017) 0.75
Bioinformatic Analysis of Gene Expression for Melanoma Treatment. J Invest Dermatol (2016) 0.75
Beyond Genomics: Multidimensional Analysis of Cancer Therapy Resistance. Trends Immunol (2015) 0.75
EZH2 as a mediator of treatment resistance in melanoma. Pigment Cell Melanoma Res (2016) 0.75
Therapeutic resistance: Multiple mechanisms to keep going. Nat Rev Cancer (2015) 0.75
Acquired resistance mechanisms to immunotherapy. Ann Transl Med (2016) 0.75
Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state. Mol Syst Biol (2017) 0.75
microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response. Genes (Basel) (2016) 0.75
Immunotherapy resistance: the answers lie ahead - not in front - of us. J Immunother Cancer (2017) 0.75
PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation. Oncoimmunology (2017) 0.75
Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. Melanoma Res (2017) 0.75
Resistance to immunotherapy: clouds in a bright sky. Invest New Drugs (2017) 0.75
Tumour heterogeneity: principles and practical consequences. Virchows Arch (2016) 0.75
Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discov (2017) 0.75
Intratumor and Intertumor Heterogeneity in Melanoma. Transl Oncol (2017) 0.75
Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases. JCI Insight (2017) 0.75
Cancer Immunotherapy, Part 3: Challenges and Future Trends. P T (2017) 0.75
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. Nat Commun (2017) 0.75
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature (2015) 7.49
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun (2012) 4.94
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov (2013) 4.39
Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell (2015) 4.16
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest (2014) 3.54
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature (2013) 3.38
Therapy-induced tumour secretomes promote resistance and tumour progression. Nature (2015) 3.07
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov (2013) 2.61
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov (2012) 2.56
Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res (2011) 2.42
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov (2012) 2.27
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun (2014) 2.10
Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal (2012) 1.95
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell (2015) 1.91
BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res (2014) 1.89
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov (2013) 1.75
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun (2014) 1.48
BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci Signal (2014) 1.44
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep (2013) 1.43
Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res (2014) 1.19
Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov (2014) 1.02
The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production. J Transl Med (2013) 1.02
Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells. J Biol Chem (2014) 0.96
Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. BMC Cancer (2015) 0.91